/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, developing our compounds, engaging in other discovery and preclinical activities, the commercial launches of AUVELITY and SUNOSI, and preparatory activities for the launch of SYMBRAVO. Subsequent to our IPO, we financed our operations primarily t…
$202.83
+$4.31 (+2.17%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-26.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 65.5% YoY with margins expanding 46.6pp.
Negative free cash flow of -$94M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$777M
▲ +65.5% YoY
Net Income (TTM)
-$192M
▲ +36.2% YoY
Op. Margin
-23.96%
▲ +46.6pp YoY
ROIC
-49.78%
▲ +23.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$72M
▲ +27.0% YoY
Op. Cash Flow (TTM)
-$71M
▲ +27.3% YoY
Net Debt
-$95M
Net Cash Position
Cash & Equiv.
$320M
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Axsome Therapeutics (AXSM)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Axsome Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Axsome Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -24.0% operating margin and a -49.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AXSM's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.